August 26, 2016 8:16 AM ET

Healthcare Providers and Services

Company Overview of Castle Biosciences Incorporated

Company Overview

Castle Biosciences Incorporated develops and commercializes diagnostic and prognostic tests for cancers. It offers DecisionDx-Melanoma, a gene expression profile test to identify stage I and II patients at high risk of metastasis based on biological information from 31 genes within their tumor tissue; DecisionDx-UM test, a highly accurate prognostic tool to measure the activity or gene expression of a set of 15 genes within an ocular melanoma tumor to identify the likelihood of metastasis; and a multivariate diagnostic test that determines the molecular signature of a glioblastoma multiforme tumor. The company also provides development programs for assays in esophageal cancer, eye cancer, me...

820 South Friendswood Drive

Suite 201

Friendswood, TX 77546

United States

Founded in 2007





Key Executives for Castle Biosciences Incorporated

Founder, Chief Executive Officer, Presiden, and Director
Age: 54
Chief Financial Officer
Age: 54
Chief Operating Officer
Chief Medical Officer
Vice President of Operations
Compensation as of Fiscal Year 2016.

Castle Biosciences Incorporated Key Developments

Castle Biosciences, Inc. Announces Clinical Results of Melanoma Gene Expression Test in Stage I and II Cohort Study

Castle Biosciences Inc. announced the results from a study evaluating the performance of its gene expression profile (GEP) test DecisionDx-Melanoma in a cohort of 356 Stage I and II melanoma patients. The data confirm findings from two previously published multicenter clinical validation studies and further support the test’s ability to identify patients’ risk of melanoma recurrence in the five years following diagnosis. Results from the study, led by Dr. Laura Ferris, are being presented in a poster at the 2016 American Academy of Dermatology (AAD) Summer Meeting. Performance of a Prognostic 31-Gene Expression Profile test to Identify High Risk Stage I and II Melanoma Patients (Abstract # 4067), 356 Stage I and II cutaneous melanoma tumors from 12 centers in the U.S. were analyzed in a CAP/CLIA-accredited laboratory using the DecisionDx-Melanoma test and classified as either low risk Class 1 or high risk Class 2. Study endpoints included recurrence-free survival (RFS), defined as time to either a regional or distant metastatic event, distant metastasis-free survival (DMFS), defined as time to any metastatic event beyond the regional node, and metastasis-free survival (MSS), defined as time from diagnosis to death documented as specifically resulting from melanoma. Topline results are, GEP test identified 71% of early stage melanoma tumors that recurred, 70% of those that metastasized distantly, and 80% of those that died from melanoma and using Cox multivariate analysis, GEP test was shown to be a significant predictor of both recurrence.

Castle Biosciences Announces Clinical Results of Melanoma Gene Expression Test in 334-Patient Performance Cohort Study at ASCO 2016

Castle Biosciences Inc. announced the results from a study evaluating the performance of its gene expression profile (GEP) test, DecisionDx®-Melanoma, in 334 new melanoma patients. The data confirmed the positive results from two previously published multicenter clinical validation studies demonstrating the test’s ability to identify patients’ risk of melanoma recurrence in the 5 years following diagnosis. The data were presented in a poster session at the 2016 American Society of Clinical Oncology Annual Meeting in Chicago, IL. A second, independent, prospective study of DecisionDx-Melanoma was also presented further confirming the results of the three prior multicenter studies. The data show that GEP classification is significantly associated with early recurrence in patients diagnosed with melanoma. With a median follow-up time of 18 months, the study found a Negative Predictive Value of 98% for disease-free survival. To date, all Stage III patients with a Class 1 result are recurrence free. The DecisionDx-Melanoma test correctly identified 16 of 18 patients who had recurrence events as high-risk (Class 2). Overall the high-risk Class 2 group had a 38% recurrence rate. Patients who were both high-risk Class 2 and Stage III had a 77% recurrence rate compared to 43% with Stage III status alone.

Castle Biosciences, Inc. Announces Appointment of Bernhard E. Spiess as Chief Operating Officer

Castle Biosciences Inc. announced the appointment of Bernhard E. Spiess to the newly created role of Chief Operating Officer. Bernhard comes to Castle Biosciences with over 35 years of clinical diagnostics experience, most recently serving as Vice President of Product Management for both Clinical Chemistry and Infectious Diseases at Beckman Coulter.

Similar Private Companies By Industry

Company Name Region
@ Home Medical, Inc. United States
@home approach, llc United States
@Home Care United States
1011 E. Pecan Grove Road, LLC United States
1125 Sir Francis Drake Boulevard Operating Company, Llc United States

Recent Private Companies Transactions

No transactions available in the past 12 months.

The information and data displayed in this profile are created and managed by Capital IQ, a Standard & Poor's company. does not create or control the content. For inquiries, please contact Capital IQ directly by clicking here.

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup

Most Searched Private Companies

Company Name Geographic Region
Lawyers Committee for Civil Rights Under Law United States
Bertelsmann AG Europe
Bloomberg L.P. United States
NYC2012, Inc. United States
Rush University United States

Sponsored Financial Commentaries

Sponsored Links

Request Profile Update

Only a company representative may request an update for the company profile. Documentation will be required.

To contact Castle Biosciences Incorporated, please visit Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at